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Results of randomized trials, comparing surgical resection with radiotherapy for early-stage lung cancer are currently not available, therefore, the precise indications and 
results of both local treatment modalities remain controversial. In a retrospective single-
institution study Robinson et al.1 analyze a large group of 338 patients who were treated 
for clinical stage I non–small-cell lung cancer (NSCLC) between 2004 and 2008. The main 
purpose was to compare the outcome of the standard procedure surgical resection with opti-
mally dosed stereotactic body radiation therapy (SBRT). SBRT was applied in 78 patients 
and lung resection in 260 patients. Although the latter group is called lobar resection group, 
15 pneumonectomies were included, reflecting more extensive disease. However, anatomi-
cal segmentectomies, which represent the surgical equivalent of SBRT, were excluded and 
bilobectomies included, so there is a shift toward larger resections for stage I NSCLC. 
Specific approaches included open thoracotomy (224 patients) and video-assisted thoracic 
surgery (36 patients). The authors conclude that surgical resection and SBRT result in com-
parable patterns of failure for clinical stage I NSCLC. Overall survival was superior for 
surgery but cancer-specific survival was not different.
Retrospective comparisons of different populations are subject to many possible 
biases, and this study is no exception. As clearly indicated by the authors, the two study 
populations were quite different. Patients in the SBRT group were older, had a higher 
comorbidity index, lower pulmonary function parameters, and a higher proportion of pre-
vious lung cancer. In contrast, in the SBRT arm more clinical T1 tumors were present. 
The main advantage of this study is that a pathological proof of NSCLC was obtained, in 
contrast to many other radiotherapy studies that also included positive lesions on positron 
emission tomography without definitive proof of malignancy.2
Although the authors state that they used uniform and coherent definitions for patterns 
of failure, there are important differences between the surgical and radiotherapy group 
when analyzing the specific criteria used. In general, complete resection for lung cancer, 
which is the most important prognostic factor when there are no distant metastases, is well 
defined. A working group of the International Association for the Study of Lung Cancer 
established precise criteria for complete, incomplete, and so-called uncertain resections.3 
Robinson et al.1 mention that optimally dosed SBRT was administered, but no definition of 
complete radiotherapy is provided. When looking at different radiotherapy studies, quite 
dissimilar dosage schemes were applied, and currently, no clear distinction is made between 
optimal and suboptimal regimes.
In a study focussing on locoregional relapse, a precise definition of recurrence is 
of utmost importance. When looking into more detail, the definition of local recurrence 
was not quite the same for SBRT and surgery. After surgical resection local failure was 
defined as failure at the bronchial stump or port site or wound. In contrast, for SBRT, 
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this was defined as progression in the region of the primary 
tumor or involved lobe.1 So, the baseline is already differ-
ent, as for SBRT local control is mainly defined as absence 
of progressive disease. What about serial diameter or volume 
measurements of the primary tumor? How is the inflammatory 
response, which invariably occurs after radiotherapy, taken 
into account? Regarding progressive disease the authors pro-
vide no details on the number of patients with a pathological 
proof of progression or recurrence. Specific causes of death 
are not listed, so, disease-free survival, which is most interest-
ing in this setting, cannot be precisely calculated.
Controversial data exist in present-day literature regard-
ing survival after radiotherapy compared with surgery. In 
a recent study that extracted data from the Surveillance, 
Epidemiology, and End-Results database between 1998 and 
2005, sublobar resection was compared with radiotherapy for 
stage IA NSCLC.4 Definitive, conventional external-beam 
radiotherapy was applied in 878 patients, and 657 patients 
underwent sublobar resection. Rather interestingly, surgi-
cal cases that did not undergo lymph node sampling were 
selected to reduce the bias provided by surgical pathological 
staging. Comorbidity scores were equal. Three-year overall 
survival was 56% for sublobar resection compared with 35% 
for radiotherapy (p < 0.0001). However, the authors of this 
article indicate that SBRT might be superior to conventional 
fractionated radiotherapy although randomized evidence is 
currently lacking.
Evaluation of nodal spread also remains an area of 
concern in patients treated with radiotherapy. In the current 
study unexpected nodal disease was encountered in more than 
20% of surgical patients, which is a high figure as all patients 
had preoperative mediastinoscopy. Precise distribution of the 
involved lymph node stations is not provided. Currently, in 
patients with positive lymph nodes, adjuvant chemotherapy 
is indicated, and the question remains how to identify these 
patients in a radiotherapy group. So, thorough nodal evalu-
ation by minimally invasive or invasive techniques, seems 
indicated in patients considered for SBRT, as recently demon-
strated and also suggested by the authors.5
As SBRT is currently more applied, thoracic surgeons 
have to cope with new challenges.6 Is resection still feasible 
with an acceptable morbidity and mortality after high-dose 
SBRT in those patients who develop local recurrence that 
may occur years after SBRT? Thoracic surgeons are also 
called upon in case of complications as cavities colonized 
with bacteria and fungi result in a persisting infectious 
state, which is difficult to control by systemic antibiotics or 
antimycotics.
The main message of this study is that a retrospective 
nonrandomized comparison of patients treated with SBRT or 
surgery, yields very heterogeneous populations, limiting the 
validity of specific conclusions from such analysis. No defi-
nite recommendations can be made for daily clinical practice. 
These limitations were also recognized in a recent article stat-
ing that a bias is introduced by different study populations, 
different definitions of recurrence, and different methods of 
classifying morbidity.7 The latter article describes a new ran-
domized trial that recently opened for accrual. In this American 
College of Surgeons Oncology Group Z4099 or Radiation 
Therapy Oncology Group 1021 trial, sublobar resection with 
or without brachytherapy is compared with SBRT in high-risk, 
operable patients with stage I NSCLC, with a diameter of 3 cm 
or less.7 Definite answers will only be provided by such large 
studies, but it will take years to complete. In the meantime, 
complete surgical resection with adjuvant therapy in specific 
subgroups remains the standard and preferred treatment for 
operable patients with early-stage lung cancer.
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